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Abstract
The use of patient reported outcome scales in clinical trials conducted by the pharmaceutical industry has become
more widespread in recent years. The use of such outcomes is particularly common for products developed to
treat chronic, disabling conditions where the intention is not to cure but to ameliorate symptoms, facilitate func-
tioning or, ultimately, to improve quality of life. In such cases, patient reported evidence is increasingly viewed as
an essential complement to traditional clinical evidence for establishing a product’s competitive advantage in the
marketplace. In a commercial setting, the value of patient reported outcomes is viewed largely in terms of their
potential for securing a labelling claim in the USA or inclusion in the summary of product characteristics in Europe.
Although, the publication of the recent US Food and Drug Administration guidance makes it difficult for compa-
nies to make claims in the USA beyond symptom improvements, the value of these outcomes goes beyond satis-
fying requirements for a label claim. The European regulatory authorities, payers both in the US and Europe,
clinicians and patients all play a part in determining both the availability and the pricing of medicinal products and
all have an interest in patient-reported data that go beyond just symptoms. The purpose of the current paper is to
highlight the potential added value of patient reported outcome data currently collected and held by the industry
for these groups.
Introduction
In recent years, the pharmaceutical market has become
characterized by more knowledgeable customers, grow-
ing cost pressure from private and public third party
payers and increasing need for product differentiation in
a highly competitive market. To ensure product success
companies must generate value propositions that go
beyond traditional safety and clinical efficacy messages.
One route to achieving this is by generating evidence on
the patient’s perspective of treatment. Such evidence is
commonly generated by using patient reported outcome
(PRO) measures to assess patient views on product effi-
cacy. PRO is an umbrella term used to describe out-
comes collected directly from the patient without
interpretation by clinicians or others[1-3]. PRO data are
collected via standardised questionnaires designed to
measure an explicit concept (construct) such as symp-
toms, functioning (activity limitations), health status/
health related quality of life (HRQL) or quality of life
(QoL).
Industry-sponsored PRO use centres predominantly
around inclusion in marketing studies, patient registries
and clinical trials. Although PRO endpoints are still
used in a minority of clinical trials their use has grown
in recent years, particularly in randomised Phase III
trials. An analysis of clinical trials registered with Clini-
calTrials.gov shows that approximately 12% of the inter-
ventional trials registered by the pharma industry and
over 15% of non-industry sponsored protocols now
incorporate some form of PRO assessment[4]. Although
for certain therapeutic areas (most notably, psychiatric
disorders) PROs may be included in clinical trials as pri-
mary efficacy indicators, commercial use of PRO out-
comes focuses predominantly on their employment as
secondary endpoints designed to provide ‘added value’
data to support key biomedical endpoints. Such ‘value’
is viewed largely in terms of their potential for securing
a labelling claim in the USA or inclusion in the sum-
mary of product characteristics (SmPC) in Europe and
in providing supporting arguments for reimbursement.
Indeed, since the publication of the US Food and Drug
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support potential claims in product labelling, discussion
on PROs and label claims has received considerable
attention both within the literature and at industry or
professional society meetings[5-7]. Consequently PROs
are routinely included in clinical trials with these objec-
tives in mind and the data used solely for these pur-
poses. However, regulators and payers are only two of
the key stakeholders with an interest in the drug licen-
sing and reimbursement process. Both clinicians and
patients now play a key role in influencing the availabil-
ity and use of pharmaceutical products. Indeed, it is the
interaction between these interested bodies that can
help or hinder a drug’sp r o g r e s st om a r k e ta n du l t i -
mately, its success as a product. The focus for the cur-
rent study is to look at whether the pharmaceutical
industry maximises the potential for generating PRO-
based added value messages both in terms of the quality
of the data collected and the relevance of those data for
key stakeholders. Ultimately, this study aims to highlight
the value in considering the use of PRO data beyond
acquiring a label claim.
Discussion
Establishing an effective PRO strategy
The formulation of an overall PRO strategy for a devel-
opment compound is a critical but often overlooked
step in the development of a high-quality value product
proposition package. The added value of PROs to the
product development strategy rests on the use of high
quality scales that address constructs of interest to the
target audience, with appropriate measurement, data
capture and reporting strategies. However, an effective
strategy requires a clear understanding of PROs to
enable a judgment of what they actually measure (and
hence, which stakeholders will be interested in the resul-
tant data) and how to assess their quality. Furthermore,
it requires company commitment to planning, often to
thinking ‘outside the box’ rather than the replication of
former approaches. Unfortunately, criteria for PRO scale
selection are occasionally restricted to issues of availabil-
ity or familiarity rather than considerations of instru-
ment relevance or quality. The use of inappropriate
i n s t r u m e n t sa n dt h el a c ko fe x p l a n a t i o nf o rt h ec h o i c e
of instruments in clinical trials has been a constant
complaint by many authors[8-11]. In some disease areas,
such as plastic reconstructive surgery and liver trans-
plantation inappropriate PROs are included in studies
since there are no gold standard instruments available
[12,13]. Occasionally, certain PRO instruments are
selected ahead of more appropriate scales because they
are considered to be a ‘standard’ in that disease area (for
example, the Dermatology Life Quality Index in psoria-
sis)[14]. Consequently, trials do not always use the most
appropriate or highest quality instruments[15]. Funda-
mentally, an effective strategy requires the allocation of
sufficient time and resources. Aggressive company time-
lines can affect the feasibility of the best-designed strate-
gies and it is not uncommon for companies to approach
PRO consultants with insufficient time for advice to be
implemented. This is particularly noted where there is a
need to develop a new instrument or provide new lan-
guage versions of an existing PRO scale.
What do PROs measure?
A well-designed PRO questionnaire should inform on an
explicit PRO concept; that is, the construct addressed by
the measure should be clearly stated by the instrument
authors. PROs commonly used as endpoints in clinical
trials and studies include measures of symptoms, function-
ing (activity limitations), health status/HRQL and QoL
(Figure 1). More recently, trials have also incorporated
PROs that address patient satisfaction, compliance and
treatment preferences. Measures of symptoms address
‘impairments’; that is, any loss or abnormality of psycholo-
gical, physiological or anatomical structure or function
[16,17]. Measures assess a deviation from an individual’s
normal biomedical status, informing on symptoms and on
the adverse effects of interventions. Examples include
measures of anxiety, pain and cough. Activity limitation
PROs address physical, social or psychological functioning;
that is, any restriction or lack of ability to perform an
activity in the manner or within the range considered nor-
mal for a human[16,17]. Examples include assessments of
activities of daily living such as dressing, walking or perso-
nal care. HRQL has been defined as ‘the capacity to per-
form the usual daily activities for a person’sa g ea n dm a j o r
social role’[18]. Thus, deviation from normality results in a
reduced HRQL. Its emphasis is on the measurement of a
combination of symptoms and functioning and, as such,
HRQL relates to health status. Consequently, measures of
HRQL are multi-dimensional, yielding a profile of scores.
The outcome of QoL is considered to be a substantively
different outcome from HRQL[19]. The most widely
implemented approach to the measurement of QoL is the
needs-based model of QoL. This postulates that indivi-
duals are driven or motivated by their needs and that the
fulfilment of these provides satisfaction[2]. Consequently,
life derives its quality from the ability and capacity of the
individual to satisfy certain human needs. For example,
the function of walking may lead to the satisfaction of sev-
eral needs including socialisation, independence and com-
munication. Needs-based QoL measures are
unidimensional and thus, yield a single score[2].
Are all PROs equal?
Determining the appropriate construct for assessment
alone does not guarantee a successful PRO evaluation
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also requires consideration of key quality standards.
There are currently thousands of PRO instruments
available to users. The Patient Reported Outcomes and
Quality of Life Instrument database (PROQOLID) cur-
rently includes 654 PRO instruments, over 500 of which
are condition-specific scales[20,21] while the On-Line
Guide to Quality-of-Life Assessment (OLGA) is
reported to include thousands of PRO scales[22,23].
However, a PRO instrument is only of value if it is well
designed. Instruments should be based on a sound, the-
oretical model of what they measure. Without this, it is
impossible to conclude that the measure has construct
validity[24]. Measures should be derived from direct
patient-input to ensure their relevance to the study
population and possess adequate psychometric and scal-
ing properties[2,25]. Instruments should adequately
sample or cover content relevant to the construct
assessed (content validity). A well-designed PRO is cap-
able of assessing patients across a broad spectrum of
disease severity. Conversely, poorly designed PROs may
be incapable of identifying changes in the construct
measured associated with treatment for very mild or
very severe patients. PROs that are highly relevant to
the patient group under study will maximise the quality
of the data collected. Irrelevant questionnaire content
can alienate respondents, making them feel that their
views are not fully appreciated. This can lead to missing
data; respondents may fail to answer questionnaires they
consider irrelevant and disaffected respondents may take
less care completing the questionnaire and miss addi-
tional questions in error. Generic scales, by definition,
contain some questions that are irrelevant to specific
patient groups and miss areas of particular importance.
The use of well-designed disease-specific scales ensures
that patients are only asked questions that are relevant,
meaningful and acceptable to them. PROs used in any
study designed to measure change should also have
excellent reproducibility. It should be noted that internal
consistency as assessed by Cronbach’sA l p h ad o e sn o t
inform on scale reproducibility but rather provides an
indication of the interrelatedness of questionnaire items
[26]. Furthermore, any scale (or sub-scale) for which the
questions are summed to produce a single score must
be unidimensional. That is, it should measure a single
underlying concept. Item Response Theory, (predomi-
nantly Rasch analysis) is now considered to be the most
efficient means of establishing unidimensionality[27-30].
Where instruments are required for multi-country stu-
dies, as is the case for most clinical trials, it is essential
to ensure that the different language versions have been
translated using suitable methods and their psycho-
metric properties established[31,32]. However, a particu-
lar challenge to global clinical development programmes
is the relevance of the content of a PRO scale to the cul-
ture and lifestyle of all country centres. While it is
u s u a l l yp o s s i b l et ot r a n s l a t eaP R Oq u e s t i o n n a i r ei n t oa
new language, it does not follow automatically that the
Figure 1 Conceptualization of PRO constructs.
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example, content on sexual behaviour that is considered
suitable by Western European respondents may be con-
sidered offensive by respondents in Southeast Asia. Cul-
tural relevance should be formally assessed and
documented for all translated versions of PRO scales.
The selection of the most appropriate PRO scales for
the trial programme may necessitate the development of
new language versions of the questionnaire. This is par-
ticularly the case for some of the more recently devel-
oped condition-specific scales. Given the expense of,
and time required for translation and psychometric
assessment of additional countries careful consideration
should be given to selecting the countries in which a
trial will be run. Collecting PRO data from a large num-
ber of countries where individual samples may be small
is less efficient than selecting larger numbers of partici-
pants from fewer countries where validated versions of
the outcome measures are already available.
The ability to produce high quality PRO instruments
has advanced considerably in recent years[25]. Further-
more, the increased need for researchers to document
and standardise their research practices has led to a
drive for higher quality scales. It is not enough to select
am e a s u r ef o ras t u d yb a s e do np r e v i o u su s ei nt h ed i s -
ease area. Selection should be based on both the rele-
vance of the content and the suitability of scale
psychometric and scaling properties in order to ensure
that the scale has the ability to measure change. In par-
ticular, the continued use of older generic scales such as
the Nottingham Health Profile (NHP)[33], the Short
Form 36 (SF-36)[34] and the EuroQoL-5D (EQ-5D)[35]
as measures to report the patient-perceived effects of
treatment is often questionable. In addition to the rele-
vance issues highlighted above, such scales, being older,
pre-date the advances in measurement science that have
taken place over the past decade. The NHP and the SF-
36 in particular, were designed for use in cross-sectional
population studies and, as such, lack the psychometric
and scaling quality expectedo fm o d e r ni n s t r u m e n t s
designed to measure change. Inviting patients to com-
plete instruments that have limited ability to demon-
strate the perceived effects of treatment raises serious
ethical questions. The use of poorly designed instru-
ments results in a wasted opportunity to demonstrate
PRO outcomes at a time when the industry can ill afford
to squander precious financial resources.
The value of PROs to key stakeholders
T h ea u d i e n c ew i t ha ni n t e r e s ti nP R Oo u t c o m e sh a s
broadened in recent years to include not only patients
and their representatives but also regulators, policy
makers, health technology assessment (HTA) authorities
and physicians. All of these stakeholders play a part in
determining both the availability and the pricing of
medicinal products and all have an interest in patient’s
v i e w so nt h ee f f e c t so ft r e a t m e n t .T h i si sp a r t i c u l a r l y
apparent for products launched in the economically
advanced nations whose health care systems are predo-
minantly concerned with the treatment of chronic, dis-
abling conditions associated with an ageing population
in a climate of restricted financial resources. Where pro-
ducts are designed to improve life quality rather than to
cure, the communication of patient-perceived effects
can provide a valuable adjunct to measures of clinical
efficacy and aid product differentiation. The question
remains, what PRO outcomes are of greatest interest to
key stakeholders.
The regulatory perspective
The key regulatory authorities have expressed interest in
seeing PRO data included within product submissions.
While the FDA has produced formal Guidance on the
use of PROs to support potential claims in product
labelling, the European Medicines Agency (EMA) has
opted not to issue similarly formal guidance at this time.
Instead, EMA has produced a Reflection Paper to pro-
vide broad recommendations on the use of PRO mea-
surement in the context of existing guidance documents
[36]. Following on from this, EMA has now launched a
Biomarker’s Qualification programme to provide a for-
mal mechanism for ratifying clinical trial endpoints,
including new or existing PROs[37].
Although the FDA’s advisory committees have
requested PRO data to be collected in clinical trials it
appears that they favour symptoms-based PROs for
label claim submissions over other potential PRO end-
points. A review of PRO labels for drugs approved in
2007 and 2008 showed that 75% of PRO label claims
were granted for signs and symptoms, 13% for activity
limitations and 13% for HRQL[38]. Conversely, EMA
currently appear to take a more flexible approach. For
the same period EMA included signs and symptoms-
based PROs in 55% of SmPCs authorised, activity limita-
tions endpoints were included in 14% and HRQL end-
points in 31% of SmPCs[38]. EMA disease-specific
guidelines frequently request PRO endpoints ranging
from symptoms to QoL data to be included as key sec-
ondary end-points. While specific questionnaires are
occasionally suggested (for example, the Ankylosing
Spondylitis Quality of Life Questionnaire; ASQoL)[39].
EMA appear to be open to the inclusion of any scale
providing it has been appropriately developed, has ade-
q u a t ep s y c h o m e t r i cp r o p e r t i e sa n di t su s ec a nb ej u s t i -
fied for the study population. Of the 81 final clinical
guidance documents currently available (for the follow-
ing disease categories/body systems: Alimentary tract
and metabolism, Cardiovascular system, Dermatologi-
cals, Genito-urinary system and sex hormones, Anti-
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modulating agents, Musculo-skeletal system, Nervous
system, and Respiratory system) from the EMA website,
39 specified guidelines for PRO inclusion as either pri-
mary (n = 5), secondary (n = 22) or both (n = 12) trial
endpoints[40].
The position of the regulatory bodies, and the FDA in
particular, has caused much debate in the pharmaceuti-
cal and health outcomes communities. International
learned societies have held workshops to debate its
impact and journals have hosted special issues devoted
to the topic[41]. While this debate has highlighted qual-
ity issues for PROs, it appears to have shifted attention,
almost exclusively, to the use of PRO data in pursuit of
the label claim. However, it would be unfortunate if this
debate removed the focus from the true purpose of
PRO data collection; that is, to inform on the patient’s
perspective on the effects of treatment.
HTA and reimbursement authorities
Heath Technology Assessments (HTA) are used in many
countries to determine the benefits or added value of
new technologies for the purpose of reimbursement and
pricing decisions and/or the establishment of clinical
guidelines[42,43]. As health expenditures soar these
bodies are increasingly concerned with assessing value
for money; particularly for new and potentially expensive
pharmaceutical products. Several countries now have for-
mal agencies with the specific remit of evaluating the
relative clinical and economic benefits of drug therapies.
In Canada, Australia and many parts of Europe societal
or patient perspectives are included as part of the HTA
process[44,45]. For example, patients’ organizations are
involved in all aspects of the consultation process of the
German Institute for Quality and Efficiency in Health
Care (IQWiG). Similarly, the UK National Institute for
Clinical Excellence (NICE) has made a public commit-
ment to include the views of patients, voluntary organisa-
tions and the general public in order to produce
guidance that reflects their views [46]. Indeed, patient
pressure was a key factor in the decision by NICE to
approve Herceptin, a treatment for early stage breast can-
cer, for use by the National Health Service[47].
The HTA’s largely recommend both quantity and
quality of life measurement parameters as part of their
evaluations. For example, NICE has recommend patient
scores the QoL in Adult Growth Hormone Deficiency
scale (QoL-AGHDA)[48] as one of the three criteria for
judging patient suitability for treatment with recombi-
nant human growth hormone[49]. Similarly, scores on
the Dermatology Life Quality Index (DLQI) are used to
judge suitability for drug treatments for psoriasis and
eczema[14,50-52].
A l t h o u g hn of o r m a lH T Aa g e n c ye x i s t sa sy e ti nt h e
USA, the recent interest in comparative effectiveness
research has prompted US commentators to call for the
HTA process to include not only of clinical outcomes,
but also “... important measures of effectiveness such as
patient-reported outcomes, including health related
quality of life, patient satisfaction, activities of daily liv-
ing, and work productivity as relevant to the various
USA stakeholders.”[53]. Indeed health payers now com-
monly seek the input of patient information (either via
direct views or PRO data) in making reimbursement
decisions. For example, the importance of addressing
subjective PRO outcomes was emphasised last year by
WellPoint, one of the largest US health benefits compa-
nies. WellPoint has issued formulary guidance to give
drug companies more detailed advice on submitting
information on a drug’s cost-effectiveness and its impact
on pharmacy and medical budgets, as well as its effec-
tiveness in improving patients’ quality of life[54]. Indeed,
In search of patient-centric evidence WellPoint carry
out its own outcomes studies to make formulary deci-
sions[55].
Clinical perspective
Clinical-rating scales, whereby the physician completes a
form to rate disease severity or treatment effects, have
long been employed in clinical practice. However, there
are often wide discrepancies between patient and clinical
views of treatment effectiveness[56-58]. Clinicians often
report fewer problems than patients, may underestimate
the severity of the problems and overestimate treatment
improvement[59-62]. For example, discrepancies have
been demonstrated between clinical and patient based
reports of pain and overall health in rheumatoid arthritis
patients, with clinicians consistently rating pain levels as
lower and health status as higher than patient ratings
[63]. Similarly, for cancer patients general practitioners
have reportedly rated pain as up to 40% lower than the
patient-based ratings on up to 57% of occasions. Physi-
cians have also been shown to consistently underesti-
mate the QoL of breast cancer patients[64]. As a result,
there is a growing awareness of the need to take
account of the patient’s views in the healthcare evalua-
tion process and the use of PROs by physicians is grow-
ing. Indeed, there have been calls to include PROs as
part of routine patient assessment in clinical practice;
either for screening purposes or to aid management of
individual patients[65]. However, the specific PROs of
interest to clinicians do not always correspond to those
of interest to patients. For example, one of the com-
monly used measures of activity limitations for Ankylos-
ing Spondylitis (AS), the Leeds Disability Questionnaire
[66] enquires about the patient’s ability to look for
objects on high shelves. However, interviews conducted
with AS patients as part of a study to develop a QoL
scale, revealed that AS patients organise their lives so
that they never have the need to use high shelves.
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important issue for clinicians to consider, such physical
limitations may be of little concern to the patient[67].
Despite these observations, publication of PRO data
can demonstrate drug benefits to clinicians. For exam-
ple, the Pfizer International Metabolic Database (KIMS)
collects data on both treated and untreated adults with
growth hormone deficiency (GHD) to provide evidence
based medicine to clinicians. Since its inception in 1984,
KIMS has routinely collected QoL data using the QoL-
AGHDA questionnaire[68]. PRO data have also been
used to predict survival and fatigue reported by cancer
patients has been shown to be a predictor of survival
[69,70]. PROs can be used to better understand patients’
symptom experience and satisfaction. This will in turn
can improve health professionals’ symptom appraisal
efforts, enabling them to provide better quality of care
and encourage compliance.
The patient perspective
Patients’ involvement in the care they receive is undoubt-
edly being given greater emphasis. Indeed, there have
been calls to embrace patients as partners in the evalua-
tion of healthcare technologies[71,72]. The American
College of Physicians has declared that the patient has a
right to self determination and the World Health Organi-
sation has stated that patient involvement in their health
care is not only desirable but a social, economic and
technical necessity[73,74]. Patients want to be involved in
the decision making process, especially when alternative
treatments exist[75]. Patients have ultimate responsibility
for many decisions taken in connection with their health.
Specifically, they decide when to seek medical advice,
whether to accept that advice and ultimately whether to
comply with prescribed medicines or whether to present
a case for an alternative product. Consequently, the
patients’ voice in relation to outcomes is being taken far
more seriously by health payers and policy makers[76].
As discussed above, a well-designed PRO strategy for
a development compound should include measures of
relevance to patients. It should be noted that patients
can (and generally will, if asked) complete any form
with which they are presented. This does not suggest
that the information collected by the questionnaire is
necessarily of interest to or of value to them. Indeed,
discrepancies exist between the specific outcomes of
interest to patients and clinicians[57,58]. For example,
patients with systemic lupus erythematosus base their
assessments of their disease activity on its psychological
and broader QoL impact, whereas clinicians base their
assessment on its physical effects[77,78]. Measures of
symptoms, functioning and HRQL can provide valuable
information about the level of impairment or disability
experienced by the patient to complement physician rat-
ings in these areas. However, they provide a framework
for assessing interventions predominantly from a clinical
rather than patient perspective. Patients with chronic
disease adapt to their condition, often replacing activ-
ities that they can no longer perform with others that
are equally satisfying. For example, a multiple sclerosis
patient with ambulatory problems can maintain a rea-
sonable level of QoL by remaining independent through
the use of a walking frame or wheelchair. Function-
based measures are unable to cope with such adaptation
making it difficult for severely ill or disabled patients to
show improvement, even following effective interven-
tions. Indeed, the emphasis placed on physical function-
ing in HRQL instruments determines that disabled
people cannot have a good ‘QoL’; a fact that is not
borne out by experience. HRQL should not be confused
with QoL. Bradley argues that ‘clinicians may be misled
into thinking that findings based on a HRQL instrument
indicate that treatments do not damage QoL when all
the data reveal is that treatments do not damage per-
ceived health’[79]. QoL measurement goes beyond the
impairments and activity limitations assessed by HRQL
instruments[80,81]. To obtain a complete picture of the
impact of disease and of the effectiveness of treatment
from the patient’s perspective, particularly when a pro-
duct cannot promise to cure or to extend a patient’s
life, assessment of QoL becomes paramount.
Undoubtedly, pressure from patients and patient advo-
cacy groups is one of the main driving forces behind the
increased focus on PROs. Capturing patients’ experience,
needs and concerns in product labels has become increas-
ingly challenging. The FDA may be unwilling to consider
PRO data beyond first order impacts (signs and symp-
toms). However, it is clear when talking to patients and
patient groups that such concerns are often of minor con-
cern to their determination of the impact of disease and
the effectiveness of treatments. Patients have very real
ideas about what states of physical and emotional well-
being (and ultimately QoL) are acceptable and may not
always agree with clinicians and regulators on whether
treatments are beneficial. This point should not be disre-
garded lightly. As it becomes increasingly common for pri-
cing models to incorporate patients’ views on the value of
products, these may be taken into account even where
they contradict those of other stakeholders[82].
Does the industry make full use of its PRO data?
A PRO strategy for a new compound requires companies
to consider all potential means of making interested par-
ties aware of relevant information. Strategies for dissemi-
nation of key messages will need to evolve to keep pace
with developments in emerging methods of communica-
tion. The key to making the best use of PRO data is to
disseminate those data as widely as possible to all key sta-
keholders. Despite the increasing use of PRO endpoints
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much of the data collected remains underutilised and fre-
quently, under or even unreported. Irrespective of
whether a successful PRO-based label claim is achieved,
PRO data collected in trials should be published in peer-
reviewed academic journals. Too often PRO data consid-
ered unsuitable for a label claim by regulatory authorities
are cast aside by the industry as unworthy of further
attention. Certainly, investigators often find it difficult to
justify the resources required to prepare a publication or
to conduct valuable secondary analyses. However, key
stakeholders are interested in PRO-evidence. As clini-
cians in particular become more leery of traditional sales
methods, academic publications become a crucial vehicle
for presenting product value messages[82]. However,
information contained in such publications has always
been accessible only to those professionals lucky enough
to be in an institution that subscribes to a particular jour-
nal. The availability of emerging technologies has effec-
tively broadened the audience able to access such
information. Patients in particular are keen to identify
information on those treatment benefits that are of inter-
est to them - and even keener to disseminate useful find-
ings through web-based networking sites.
In addition to providing data on treatment efficacy, sec-
ondary analysis can be conducted on PRO data collected
in clinical trials to provide disease or drug intelligence.
An exploration of the key demographic (age, gender etc.)
and clinical factors (duration, severity, diagnostic group-
ings etc) influencing for example, patient perceived sever-
ity of condition, functional impact or QoL can further
our understanding of the disease from the patient’sp e r -
spective[83]. This can provide an exploration of key fac-
tors that predict and explain functional and QoL impact,
information on mediating factors in disease severity and
implications for treatment, especially product targeting.
Secondary analysis can provide market intelligence effec-
tively at a reduced cost (as the data collection has been
conducted for other purposes) that can be fed into com-
pany strategies for targeted drug development and mar-
keting. Again, disseminating such information via peer-
reviewed academic journals and supporting dissemina-
tion via Internet-based technologies is to be encouraged.
Presenting well thought out PRO-based information,
whether this relates to product effectiveness or disease
intelligence, demonstrates company commitment to
patients and enhances the company’s reputation with
patient groups and clinicians. The question that the
industry should be asking itself is “a r ew em a k i n gt h e
best use of the data we collect and hold"?
Conclusions
The inclusion of PRO data in label claim submissions is
likely to remain for some time the key goal of PRO-
endpoints use in clinical trials. Nevertheless, there are
limitations to the use of such data in this context; not
least the preference of the FDA for symptom-based
data. Although key stakeholders, including patients,
place high premium on PROs the new regulatory gui-
dance places high hurdles for companies to make claims
beyond symptom improvements. However, the value of
PROs goes beyond satisfying requirements for an FDA
label claim. EMA, payers both in the US and Europe,
clinicians and patients and their representatives all have
an interest in PRO data that go beyond just symptoms.
The competitive advantage lies in identifying broader
PRO outcomes that are relevant to key stakeholders,
identifying the best possible measures to assess these
and in finding the most innovative ways of communicat-
ing PRO-value messages.
As the industry can no longer rely on traditional phar-
maceutical sales models alone companies are increasingly
looking to new forms of communication technology to
demonstrate the value of products to a wider audience
beyond the traditional physician pool. While a QoL label
claim may be illusive in the current climate, the publica-
tion of an article demonstrating the benefits of a drug
t r e a t m e n tb a s e do nd a t af r o maw e l ld e v e l o p e dP R O
scale is likely to have a far reaching impact. The publica-
tion of data based on such PROs is likely to find its way
onto patient-web sites and such information is of interest
to both patients and patient advocacy groups alike.
Furthermore, these are precisely the kind of data that
patient advocacy groups feel they need in order to lobby
payers and politicians in order to gain access to newer,
often more expensive medical products.
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